AmbioPharm Revenue and Competitors

AmbioPharm, Inc. (APi) is a full-service peptide manufacturing company headquartered at our North Augusta, SC cGMP production site. Our second cGMP facility in Shanghai, China, performs process development & optimization, and manufactures building blocks, raw materials, and custom peptides at very large scale. Both our cGMP facilities are capable of handling any manufacturing scale required to produce bulk peptides to custom specifications using a wide range of skill sets in both solid and solution-phase chemistry. Our management team has over 100 years cumulative experience running pilot to commercial scale production. We also perform organic conjugations to small molecules, proteins, toxoids, antifungals, KLH, and PEG. Management Team: Chris J. Bai, Ph.D, President and CEO with 22 years of experience in the peptide industry. Stephen Kiel, M.B.A., CPA, Chief Financial Officer of Ambio Holdings, the parent of Ambio and AmbioPharm with over 20 years of experience. Jim Hampton, B.S., MS, Executive Vice President of Business Development and cGMP Sales with 23 years of experience in the peptide industry. Robert Geiger, Ph.D, MBA, Vice President of Quality with 16 years of experience in the peptide industry. Mike Pennington, Ph.D, Vice President of Technical Operations with over 20 years combined experience in the Bio-science/Peptide Industry. Simrat Singh, Ph.D, Vice President of QC, ARD and RA with over 16 years of combined experience in Analytical, R&D, Formulation, Drug Product Development, RA and QC.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power